



PRESS RELEASE

NORAKER announces it is one of the awardees of the highly selective European Union's Horizon 2020 Research and Innovation Program "SME instrument". The grant of 2.5M€ will fund scaling-up of implants for regenerative orthopaedic surgery, to offer full healing to patients suffering from a bone, ligament or tendon injury.

"Only 94 out of 2025 projects have been selected for this cut-off"

[About EIC SME Instrument program \(part of EU Research&Innovation "Horizon 2020"\)?](#)

The EIC SME Instrument is a public program that funds risk innovation in small businesses. It funds market-creating innovation in disruptive small businesses that have significant growth potential and global ambitions. The EIC SME Instrument is part of Horizon 2020 – the EU's 80 billion euros funding program for Research and Innovation for 2014-2020.

The EIC SME Instrument aims at supporting European top-class innovators, entrepreneurs, small companies and scientists; and favors the emergence of future leaders capable of improving tomorrow's world through the excellence of their expertise and know-how. Chances of obtaining the grant are extremely limited: a mere 3 to 5%!

For the cut-off of June 2019, the European Commission received 2025 proposals. Small and medium-sized enterprises (SMEs) from 40 countries submitted proposals. Companies that pass the initial selection stage were invited to Brussels in July, to pitch in front of a jury of investors and business experts.

At the end only 94 (4.6%) companies were selected and French SMEs were the most successful with 11 companies selected for funding. This shows how intense the competition is under the programme and demonstrates the high quality of the proposals funded. 25% of the companies funded under the EIC SME Instrument are in the 10% fastest growing companies in Europe according to Venture Radar.

NORAKER's project "REBOOT" aims at developing first-in-class implants for regenerative orthopaedic surgery to offer full healing to patients suffering from a bone, ligament or tendon injury. REBOOT is one of the 94 granted projects selected out of 2025 proposals, with a grant of 2.5M€.

[About Noraker](#)

NORAKER is located in Lyon, France, in the heart of the country's pharmaceutical and medical region (PharmaValley). NORAKER is committed each day to innovation in the fields of orthopaedics surgery, with the guiding principle of **improving patient comfort**. Since 2005, NORAKER is specialized in the design, manufacturing and marketing of **synthetic and bioabsorbable medical devices** for orthopaedic surgery. **The vision of Noraker is to provide full healing to patients suffering from a bone, ligament or tendon injury.**



“As the expert manufacturer of Bioactive Glass, we believe that every single patient in the world should profit from best-in-class medical technologies in the area of bone regeneration tissue engineering and regenerative medicine. From scientific discovery and clinical trials to product manufacturing, we perform our research and innovation work with passion, producing in the end truly innovative technologies that make a real difference in the field of human health.

We are proud to share our knowledge and improve our products with healthcare specialists who are committed to offering patients the best possible treatment.”

Providing a high level of care enhances the patient's quality of life, and the clinician's professional reputation. For NORAKER, patient care represents a long-term commitment, to healthcare professionals and to their patients.

This funding will enable NORAKER to launch a new technological challenges to meet the expectations of the market, with a single objective: Improve the comfort of the patient.



"The Horizon 2020 grant is both a great facilitator to achieve our goals and, due to the strict selection process we have undergone, a strong endorsement of our company and technology".

"It is in NORAKER's DNA to develop the most innovative biomaterials to preserve the quality of the bone structure. With our range of products and projects developments, we aim to contribute to the transition of orthopaedic surgery towards a regenerative discipline.

We are ready to take on the challenge to become a reference company in Europe with a global reach and to create the niche segment of bioactive implant for true regenerative surgery."

Céline Saint Olive Baque, CEO of NORAKER